IP Library › Patent Application 19293630
Patent Application
App. No. 19/293,630

COMPOSITIONS AND METHODS FOR INDUCED TISSUE REGENERATION IN MAMMALIAN SPECIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/293,630
Abstract

Aspects of the present invention include methods and compositions related to the modulation of molecules regulating the regenerative potential of cells and tissues in the embryonic state and the loss thereof in later fetal and adult stages of development. Said methods and compositions have uses in research in stem cell biology and in increasing regenerative potential in fetal and adult tissues otherwise incapable of regeneration.

Claims (26)

1 . A method of enhancing tissue or organ regeneration in a subject comprising administering to the subject one or more agents that inhibit COX7 A1 and one or more agents that inhibit one or more genes or gene products chosen from COMT, TRIM4, CAT, PSMD, SHMT, LOC205251, ZNF280D, S100A6, MGMT, ZNF280D, DYNLT3, NAALADL1, TSPYL5, IAH1, C18orf56, RPS7, FDPS, ELOVL6, INSIG1, ACAT2, and MAOA.

2 . The method of claim 1 , wherein the subject is a mammal.

3 . The method of claim 2 , wherein the mammal is a human.

4 . The method of claim 1 , wherein the tissue is connective tissue.

5 . The method of claim 1 , wherein the tissue is skin.

6 . The method of claim 1 , wherein the one or more agents are administered at the site of a wound.

7 . The method of claim 1 , wherein administering the one or more agents to the subject inhibits expression of the genes ACTA2 and COLIA1 at the site of administration.

8 . The method of claim 1 , wherein the one or more agents is a nucleic acid.

9 . The method of claim 8 , wherein the nucleic acid is RNA.

10 . The method of claim 9 wherein the RNA is a double stranded RNA.

11 . The method of claim 9 , wherein the RNA is siRNA.

12 . The method of claim 1 , wherein the one or more agents is a protein.

13 . The method of claim 12 , wherein the protein is an antibody.

14 . A kit comprising one or more agents that inhibit COX7A1 and optionally one or more agents that inhibit one or more genes chosen from COMT, TRIM4, CAT, PSMD, SHMT, LOC205251, ZNF280D, S100A6, MGMT, ZNF280D, DYNLT3, NAALADL1, TSPYL5, IAH1, C18orf56, RPS7, FDPS, ELOVL6, INSIG1, ACAT2, and MAOA.

15 . The kit of claim 14 , wherein the one or more agents that inhibits COX7 A1 is a nucleic acid.

16 . The kit of claim 15 , wherein the nucleic acid is RNA.

17 . The kit of claim 16 wherein the RNA is a double stranded RNA.

18 . The kit of claim 16 , wherein the RNA is siRNA.

19 . The kit of claim 14 , wherein the one or more agents is a protein.

20 . The kit of claim 19 , wherein the protein is an antibody.

21 . The kit of claim 14 , wherein the one or more agents that inhibits one or more genes chosen from COMT, TRIM4, CAT, PSMD, SHMT, LOC205251, ZNF280D, S100A6, MGMT, ZNF280D, DYNLT3,NAALADL1, TSPYL5, IAH1, C18orf56, RPS7, FDPS, ELOVL6, INSIG1, ACAT2, and MAOA is a nucleic acid.

22 . The kit of claim 21 , wherein the nucleic acid is RNA.

23 . The kit of claim 22 wherein the RNA is a double stranded RNA.

24 . The kit of claim 22 , wherein the RNA is siRNA.

25 . The kit of claim 14 , wherein the one or more agents is a protein.

26 . The kit of claim 25 , wherein the protein is an antibody.